Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study

被引：0
|
作者：
Vermersch, P.
Comi, G.
Cook, S.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. Soelberg
Kurukulasuriya, N.
Viglietta, V.
Chang, P.
Papasouliotis, O.
Greenberg, S.
机构：
[1] Univ Lille Nord de France, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Univ Med & Dent, Newark, NJ USA
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Univ Miami, Miami, FL USA
[6] Univ Erlangen Nurnberg, Bamberg, Germany
[7] Copenhagen Univ Hosp, Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2011年 / 258卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [21] Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S206 - S206
  • [22] Effectiveness Of Cladribine Tablets In Patients With Relapsing-remitting Multiple Sclerosis With Baseline EDSS ≥3.5 Or ≤3.0 In CLARITY
    Comi, G.
    Pardo, G.
    Dangond, F.
    Aldridge, J.
    Lemieux, C.
    Rammohan, K.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 42 - 43
  • [23] Cladribine Tablets Demonstrate Similar Efficacy In Male And Female Patients With Relapsing-remitting Multiple Sclerosis In CLARITY
    Pardo, G.
    Dangond, F.
    Aldridge, J.
    Lemieux, C.
    Bowen, J. D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 40 - 40
  • [24] Efficacy of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study
    Rieckmann, P.
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Sorensen, P.
    Vermersch, P.
    Chang, P.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (10) : 1283 - 1283
  • [25] Safety of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S128 - S128
  • [26] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
  • [27] Economic analysis for introduction of cladribine tablets as a treatment for relapsing-remitting and high disease activity multiple sclerosis in Kuwait
    Alroughani, R.
    Al-Melh, M. A.
    Farouk, S.
    Abokoura, A.
    Alsultan, E.
    Boshra, A.
    Alcharif, R.
    Ojeil, R.
    Basu, S.
    Verma, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 310 - 311
  • [28] Relapses and lymphocyte counts before and after rescue therapy in the phase III, 96-week, double-blind, placebo-controlled CLARITY study of cladribine tablets for relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Giovannoni, G.
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Vermersch, P.
    Kurukulasuriya, N.
    Hamlett, A.
    Galazka, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S411 - S411
  • [29] CLARITY: an analysis of severity and frequency of relapses in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets or placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 258 - 259
  • [30] CLARITY: An Analysis of Severity and Frequency of Relapses in Patients with Relapsing-remitting Multiple Sclerosis Treated with Cladribine Tablets or Placebo
    Schippling, S.
    Sormani, M. P.
    De Stefano, N.
    Giovannoni, G.
    King, J.
    Galazka, A.
    Keller, B.
    Alexandri, N.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 466 - 467
12345